Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, an

The global central nervous system therapeutics market size is expected to reach USD 381.27 billion by 2034, according to a new study by Polaris Market Research. The report “Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The central nervous system (CNS) therapeutics market encompasses drugs and treatments for neurological disorders like Alzheimer's, Parkinson's, epilepsy, and depression, focusing on improving brain and spinal cord health and function.

The central nervous system (CNS) therapeutics market is expanding due to the growing incidence of CNS cancers, including brain tumors, gliomas, and other types. The increasing number of diagnoses is driving demand for effective treatments. For example, the American Brain Tumor Association reports that 90,000 people in the US are diagnosed with a primary brain tumor each year, reflecting a rising trend in cases. Additionally, the aging population is contributing to the increase in CNS cancer cases, as older adults are more vulnerable to cancer-causing radiation.

The central nervous system (CNS) therapeutics market growth is being driven by increased government spending on healthcare. Both governments and private sectors are investing more in healthcare, which has led to a stronger focus on developing effective treatments for CNS disorders such as depression, anxiety, and Alzheimer’s disease. For example, healthcare expenditure in 2021 accounted for 10.3% of total GDP, according to the World Bank Group. This financial support has fostered research and innovation, resulting in the introduction of cost-effective therapies.

The central nervous system therapeutics market is growing due to advanced diagnostic technologies that make it easier to identify neurological disorders. These advancements lead to earlier and more accurate diagnoses and lead to an increased demand for effective treatments.

Central Nervous System Therapeutics Market Report Highlights

Based on drug class, the CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market due to the rising prevalence of attention deficit hyperactivity (ADHD) and sleep disorders.

By distribution channel, the hospital pharmacies segment dominated the central nervous system therapeutics market in 2024 due to the rising number of hospital admissions for neurodegenerative diseases, such as Alzheimer's and Parkinson's.

In 2024, North America had the largest revenue share in the central nervous system therapeutics market due to the rising prevalence of Alzheimer’s disease.

The central nervous system therapeutics market in India is projected for substantial growth, driven by the growth of the pharmaceutical industry.

A few of the global key market players are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

Polaris market research has segmented the central nervous system therapeutics market report on the basis of disease, drug class, distribution channel, and region:

By Disease Outlook (Revenue – USD Billion, 2020–2034)

• Neurovascular Diseases
• CNS Trauma
• Mental Health
• Neurodegenerative Diseases
• Alzheimer’s Disease
• Parkinson's Disease
• Multiple Sclerosis
• Huntington’s Disease
• Amyotrophic Lateral Sclerosis
• Others
• Infectious Diseases
• CNS Cancer
• Others

By Drug Class Outlook (Revenue – USD Billion, 2020–2034)

• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific

Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa